Loading clinical trials...

Efficacy and Safety of Oral Controlled-release Nicotinic Acid (CIR-NA) for the Remission of Prediabetes. (CONCEPT) | Clinical Trials | Clareo Health

NOT_YET_RECRUITINGPHASE2

Efficacy and Safety of Oral Controlled-release Nicotinic Acid (CIR-NA) for the Remission of Prediabetes. (CONCEPT)

A Phase II, Randomised, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Oral Controlled-ileal-release Nicotinic Acid (CIR-NA) for Inducing Remission in Subjects With Prediabetes

NCT07286747•University Hospital Schleswig-Holstein

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to prevent the change from prediabetes (a pre-stage of type 2 diabetes mellitus (T2DM)) to T2DM in participants with prediabetes using oral CIR-NA (a nicotinic acid formulation that is designed to be released after reaching the ileum) which targeted the gut microbiota. The main questions it aims to answer are: 1. Is CIR-NA effective and does it prevent the change from prediabetes to T2DM? 2. Is the safety of CIR-NA that was observed in the Phase I clinical trial confirmed in subjects with prediabetes? Researchers will compare CIR-NA to a placebo (a look-alike substance that contains no drug) in terms of an extended safety evaluation including safety laboratory assessments, physical examination, vital signs and 12-lead ECG. Participants will: Take CIR-NA or a placebo every day for 26-weeks. Visit the clinic at week 1 and subsequently once every 4 weeks for checkups and tests. Receive standardized lifestyle recommendations regarding nutrition and physical activity during the intervention.

Detailed Description

The study is a multi-centre, randomised, double-blind, placebo-controlled trial evaluating the efficacy and safety of CIR-NA in participants with prediabetes. The trial includes a 26-week intervention period, which is expected to provide adequate time for prediabetes remission and a 4-week follow-up (FU) period. A total of 390 male and female participants with a BMI of ≥ 20 kg/m² with prediabetes will be random-ised into three arms with 130 participants each in the CIR-NA (100 mg/d or 200 mg/d CIR-NA) and placebo groups. During the intervention, two indistinguishable tablets (CIR-NA and/or placebo) will be administered orally once daily. After screening and baseline assessment (including randomisation and IMP dispensing), 7 regular visits during treatment and one FU visit after 4 weeks are scheduled.

Eligibility

Age

18 - 79 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Male and female participants ≥ 18 to \< 80 years of age (at the time of signing the informed consent).
•2. Body mass index ≥ 20 kg/m².
•3. Ability to understand and comply with the protocol.
•4. Signed written informed consent.
•5. Diagnosed prediabetes according to the current EASD/DDG guidelines. Prediabetes is present if at least one value is in the prediabetes range, but no value is in the T2DM range.
•6. Subgroup-specific: MASLD fibrosis score ≥ -1.455.

Exclusion Criteria

•1. Presence or a history of type 2 diabetes mellitus according to the current EASD/DDG guidelines.
•2. Participants with relevant medical conditions (based on evaluation of medical history and screening assessments), unstable and uncontrolled underlying diseases, e.g., hypothyroidism, asthma, COPD or arterial hypertension, can be excluded per judgment of the Investigator.
•3. Renal impairment (glomerular filtration rate \<60 ml/min/1.73).
•4. Impairment of hepatic function (one or more of liver enzymes alanine transaminase, aspartate transaminase and gamma glutamyl transferase \[\> 3-fold compared to normal range\]).
•5. Current infection with hepatitis B or C.
•6. Clinically relevant abnormal findings in medical history or screening assessments which, in the opinion of the Investigator, may put the participant at risk when participating in the trial or provide difficulties in interpreting the trial data.
•7. Current or history of malignancy except for completely resected basal cell carcinoma and squamous cell carcinoma of the skin.
•8. Alcohol or drug abuse within the last 2 years at the discretion of the Investigator.
•9. Subgroup-specific: Any circumstances which could contradict MRI and MRS imaging. For details, see Informed Consent Form (ICF) for additional examinations.
•10. Regular use of any prescribed or over-the-counter medication, food supplements or herbal preparations, which cannot be terminated 3 weeks before baseline and during the full duration of the trial. Pain medication (e.g., ibuprofen or paracetamol), topical allergy medicines, hormone replacement therapies and oral contraceptives according to label are allowed. Medications in stable doses for controlling stable underlying diseases (see exclusion criterion 2) are also allowed per judgment of the Investigator.
+10 more criteria

Locations (1)

University Medical Center Schleswig-Holstein, Campus Kiel

Kiel, Germany

Key Dates

Start Date

January 1, 2026

Primary Completion Date

May 1, 2028

Completion Date

December 31, 2028

Last Updated

December 16, 2025

Enrollment

390

ESTIMATED participants

Conditions

Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)

Interventions

controlled-ileal-release nicotinic acid as multiple dose 100 mg/day

DRUG

controlled-ileal-release nicotinic acid as multiple dose 200 mg/day

DRUG

controlled-ileal-release nicotinic acid as multiple dose placebo

DRUG

Contacts

Corinna Geisler, PhD

CONTACT

+4943150022446 corinna.geisler@uksh.de

Matthias Laudes, Prof. Dr.

CONTACT

+49 431 500 22217 matthias.laudes@uksh.de

Resistance Training for the Improvement of Glycemic Control in Prediabetes

NCT06697756

Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 16, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions